Search Results
Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies
Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML
Eunice Wang, MD, on next-generation sequencing and treatment selection in AML
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important
Eunice S. Wang, MD, discusses the Quantum First Study
Targeting AML with multimodal immunotherapeutic approaches
Eunice S. Wang, MD, discusses the importance hitting the FLT3 target
Crenolanib plus 7+3 chemotherapy in adults with newly diagnosed FLT3-mutated AML.
Radio-immunotherapeutics in AML: bridge to transplant
